Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7284088 | 0.86 | RAD52 (0.50) | ELANERAD52KMT2ARECQLALDH1A1 | |
| SCHEMBL6968546 | 0.86 | ELANE (0.47) | ELANERAD52KMT2ARECQLALDH1A1 | |
| SCHEMBL8993820 | 0.85 | ELANE (0.52) | ELANERAD52KMT2ARECQLALDH1A1 | |
| SCHEMBL6975296 | 0.84 | LMNA (0.49) | ELANERAD52KMT2ARECQLALDH1A1 | |
| SCHEMBL7234130 | 0.82 | RAD52 (0.56) | ELANERAD52KMT2ARECQLALDH1A1 | |
| SCHEMBL20945000 | 0.81 | NPSR1 (0.49) | ELANERAD52KMT2ARECQLALDH1A1 | |
| SCHEMBL15803827 | 0.81 | ELANE (0.48) | ELANERAD52KMT2ARECQLALDH1A1 | |
| SCHEMBL8265639 | 0.81 | RAD52 (0.55) | ELANERAD52KMT2ARECQLALDH1A1 | |
| SCHEMBL3713978 | 0.80 | RAD52 (0.52) | ELANERAD52KMT2ARECQLALDH1A1 | |
| SCHEMBL15804004 | 0.80 | ELANE (0.70) | ELANERAD52KMT2ARECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415345-B | Pyridazinone-based broad-spectrum anti-influenza inhibitors | 豪夫迈·罗氏有限公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3478671-B1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-05-13 | — | — | EP | disclosed |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20030181498-A1 | Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin | ASTRAZENECA AB (SE) | 2003-09-25 | — | — | US | disclosed |
| EP-1272487-A1 | BICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF THE INTERACTION BETWEEN THE INTEGRIN ALPHA4BETA1 RECEPTOR AND VCAM-1 AND/OR FIBRONECTIN | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001053295-A1 | BICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF THE INTERACTION BETWEEN THE INTEGRIN ALPHA4BETA1 RECEPTOR AND VCAM-1 AND/OR FIBRONECTIN | ASTRAZENECA AB (SE) | 2001-07-26 | — | — | WO | disclosed |
| CN-1179151-A | Lactam-containing hydroxamic acid derivatives, process for their preparation and their use as inhibitors of matrix metalloproteinases | PROCTER & GAMBLE (US) | 1998-04-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181498-A1 | Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin | VCAM1, FN1, ITGA4 | ELANE 1055/4885RAD52 4625/4885KMT2A 3232/4885 |
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | ABCG2, PIR, PRNP | ELANE 2561/4885RAD52 3214/4885KMT2A 2799/4885 |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | ABCG2, PIR, PRNP | ELANE 2561/4885RAD52 3214/4885KMT2A 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.